How Wells Fargo Currently Rates ZIOPHARM (NASDAQ:ZIOP)
In analysts note issued today, Wells Fargo analysts have begun ZIOPHARM (NASDAQ:ZIOP) coverage with “Underperform” rating.
Approximately 2.22M shares of stock traded hands. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has risen 28.05% since May 1, 2015 and is uptrending. It has outperformed by 30.83% the S&P500.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The company has a market cap of $1.40 billion. The Firm is engaged in the acquisition, development and commercialization of a portfolio of cancer therapies through synthetic biology. It currently has negative earnings. The Company’s pipeline includes a number of cell therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.
According to Zacks Investment Research, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.” Get a free copy of the Zacks research report on ZIOPHARM Oncology Inc. (ZIOP).